Core Viewpoint - Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Kintor Pharmaceutical-B (02171) being included in the Hang Seng Composite Index, effective after market close on March 6, 2026, and effective from March 9, 2026 [1] Group 1 - Kintor Pharmaceutical-B is likely to be included in the Stock Connect program due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - Kintor Pharmaceutical-B announced a strategic cooperation agreement on February 12, 2026, through its wholly-owned subsidiary, Shanghai Kexing Diagnostics, with Shanghai Jinguang Enterprise Development, a key platform enterprise in Shanghai's Jinshan District [1] - The total investment for the strategic cooperation is not to exceed RMB 370 million, aimed at establishing an advanced CAR-T cell therapy product commercialization production base in Jinshan District, Shanghai [1]

Group 1 - The core point of the article is that Jingwei TianDi (02477) has been included in the Hang Seng Composite Index, with changes effective from March 9, 2026, following the quarterly review by the Hang Seng Index Company on February 13, 2025 [1] - The inclusion of Jingwei TianDi in the index may lead to its eligibility for the Hong Kong Stock Connect, as it meets various criteria including market capitalization, liquidity, and listing duration [1] - For the six months ending June 30, 2025, Jingwei TianDi reported revenue of RMB 90.068 million, a year-on-year decrease of 15.1%, and a net profit attributable to shareholders of RMB 7.717 million, down 28.02%, with earnings per share of 0.77 cents [1]

招股书显示，健康160是富有经验的中国医药健康用品批发商及领先的数字医疗综合服务提供商。公司 为客户提供各种医药健康用品，以及全面的数字医疗健康解决方案。此外，该公司亦通过在线医疗健康 服务平台-健康160平台提供数字医疗健康解决方案，赋能整个医疗健康产业链上的各平台参与方。截至 2025年3月31日，健康160的平台自成立以来已累计连接超过44,600家医疗健康机构。 智通财经APP获悉，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果， 其中健康160(02656)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9 日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，健康160有可能 被调入港股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 ...

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Xirui (02507) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the investable scope of Hong Kong Stock Connect [1] - According to CICC's research report, Xirui is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - On February 3, Xirui launched the VisionJet G3 new product, which features price increases and upgrades in intelligence and comfort [1] - West Securities believes that with the gradual acquisition of new orders for better-structured products like VisionJet G3 and SRG7+, the overall product structure will improve year-on-year, enhancing profitability [1]

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of June 30, 2025, with "沪上阿姨" (02589) being included in the Hang Seng Composite Index, effective after market close on September 5, 2025, and effective from September 8, 2025 [1] - According to Huatai Securities research report, "沪上阿姨" is likely to be included in the Stock Connect program due to meeting various criteria including market capitalization, liquidity, and listing duration [1] - "沪上阿姨" announced that on July 4, 2025, the board approved a proposal to convert up to 35,255,992 shares of unlisted domestic shares into H-shares, representing approximately 33.51% of the total issued share capital as of the announcement date [1]

Group 1 - The core point of the article is that Zhengli New Energy (03677) has been included in the Hang Seng Composite Index, with the changes effective from September 8, 2025, following the quarterly review by the Hang Seng Index Company [1] - The inclusion in the index may lead to Zhengli New Energy being added to the Hong Kong Stock Connect, as it meets various criteria including market capitalization, liquidity, and listing duration [1] - Zhengli New Energy expects to report a net profit ranging from approximately RMB 198 million to RMB 243 million for the six months ending June 30, 2025, a significant increase compared to a net loss of approximately RMB 130 million in the same period last year [1]

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of June 30, 2025, with 康耐特光学 (Conant Optical) being included in the Hang Seng Composite Index, effective after market close on September 5, 2025, and effective from September 8, 2025 [1] - 康耐特光学 is likely to be included in the Hong Kong Stock Connect due to meeting various criteria including market capitalization, liquidity, and listing duration, as reported by Huatai Securities [1] - CICC initiated coverage on 康耐特光学 with an "outperform" rating and a target price of HKD 54.00, based on a P/E valuation method corresponding to a 35x P/E for 2026, with expected EPS of HKD 1.14 and HKD 1.42 for 2025 and 2026 respectively, indicating a CAGR of 26% from 2024 to 2026 [1] Group 2 - 康耐特光学 is recognized as a global leader in resin lens manufacturing, with advanced R&D capabilities and stable customer relationships, suggesting potential for sustained growth through customized lenses, proprietary brands, and smart glasses development [1]

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of June 30, 2025, with Boleton (01333) being included in the Hang Seng Composite Index, effective after market close on September 5, 2025, and effective from September 8, 2025 [1] - Boleton is likely to be included in the Hong Kong Stock Connect due to meeting various criteria including market capitalization, liquidity, and listing time, as reported by Huatai Securities [1] - Boleton announced a construction contract with Hunan Bairui for the Boleton Electric Wide-body Dump Truck and Unmanned Driving Innovation Center project, with a total contract value of RMB 99.5 million [1]

Core Viewpoint - The inclusion of药捷安康-B (02617) in the Hang Seng Composite Index is expected to enhance its visibility and liquidity in the market, with potential adjustments to the Hong Kong Stock Connect investment scope [1] Group 1: Company Developments -药捷安康-B has been included in the Hang Seng Composite Index, with the change effective from September 8, 2025, following the announcement on August 22 [1] - The company’s self-developed multi-target kinase inhibitor,替恩戈替尼 (TT-00420), has received Fast Track designation from the FDA for the treatment of metastatic castration-resistant prostate cancer [1] -替恩戈替尼 is currently in global Phase III registration trials, targeting FGFR/VEGFR, JAK, and Aurora kinases for its anti-tumor effects, showing potential efficacy in treating various solid tumors in ongoing clinical trials in the US and China [1] Group 2: Market Implications - The inclusion in the Hang Seng Composite Index may lead to an increase in the stock's market capitalization and liquidity, as it meets criteria such as market value, liquidity, and listing duration [1] - There is a possibility that药捷安康-B could be added to the Hong Kong Stock Connect, further broadening its investor base [1]

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of June 30, 2025, with the inclusion of Jiangsu Hengrui Medicine Co., Ltd. (02617) in the Hang Seng Composite Index, effective after market close on September 5 and starting September 8 [1] - According to Huatai Securities research, Jiangsu Hengrui Medicine Co., Ltd. may be included in the Stock Connect program due to meeting various criteria including market capitalization, liquidity, and listing duration [1] Group 2 - Jiangsu Hengrui Medicine Co., Ltd. announced that its self-developed multi-target kinase inhibitor, TT-00420, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer [1] - The company stated that TT-00420 is currently in global Phase III registration trials, targeting FGFR/VEGFR, JAK, and Aurora kinases to exert anti-tumor effects, with clinical trials in the U.S. and China showing potential efficacy in treating various solid tumors [1]